Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that results from a pivotal study with HALAVEN® (eribulin mesylate), a novel anticancer agent discovered and developed by the company, will be published in the medical journal The Lancet1)...
More...